GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ABL Bio Inc (XKRX:298380) » Definitions » Institutional Ownership

ABL Bio (XKRX:298380) Institutional Ownership : 8.47% (As of Sep. 21, 2024)


View and export this data going back to 2018. Start your Free Trial

What is ABL Bio Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, ABL Bio's institutional ownership is 8.47%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, ABL Bio's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, ABL Bio's Float Percentage Of Total Shares Outstanding is 0.00%.


ABL Bio Institutional Ownership Historical Data

The historical data trend for ABL Bio's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ABL Bio Institutional Ownership Chart

ABL Bio Historical Data

The historical data trend for ABL Bio can be seen below:

2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31 2024-07-31 2024-08-31
Institutional Ownership 8.49 8.49 9.59 9.67 9.65 9.50 9.41 9.72 8.89 8.47

ABL Bio Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


ABL Bio Business Description

Traded in Other Exchanges
N/A
Address
2nd Floor, 16 Daewangpangyo-Ro 712, Beon-Gil, Bundang-Gu, Gyeonggi-do, Seongnam-si, KOR, 13488
ABL Bio Inc is a Korean biotech research company. The company is engaged in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline products include ABL001 an Bispecific Antibody, ABL201-205 an Antibody Drug Conjugate, T cell engager, Dual Immune Cell Targeting BsAb an Immuno-Oncology, ABL301 an BBB-Penetrating Bispecific Antibody.

ABL Bio Headlines

No Headlines